Skip to main content

Advertisement

SpringerLink
Log in

MiR-145 suppresses cell proliferation and motility by inhibiting ROCK1 in hepatocellular carcinoma

  • Original Article
  • Published:
Tumor Biology

Abstract

MicroRNAs (miRNAs) play key roles in cancer development and progression. In the present study, we investigated the role of miR-145 in the progression of hepatocellular carcinoma (HCC). Ten HCC cell lines and samples from 96 patients with HCC were analyzed for the expression of miR-145 by quantitative real-time polymerase chain reaction (qRT-PCR). Overexpression of miR-145 was established by transfecting mimics into HepG2 and QGY-7703 cells. Cell proliferation and cell migration were assessed by cell viability assay and transwell assay. Western blot was to verify ROCK1 as a novel target gene of miR-145. Our results showed that miR-145 was frequently downregulated in HCC tumors and cell lines. Overexpression of miR-145 in HCC cell lines significantly inhibited cell proliferation, migration, and invasion in vitro. ROCK1 was identified as a target of miR-145, and ectopic expression of miR-145 downregulated ROCK1. Together, these findings indicate that miR-145 acts as a tumor suppressor and its downregulation in tumor tissues may contribute to the progression and metastasis of HCC through a mechanism involving ROCK1, suggesting miR-145 as a potential new diagnostic and therapeutic target for the treatment of HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15 Suppl 4:5–13.

    Article  PubMed  Google Scholar 

  2. Teo EK, Fock KM. Hepatocellular carcinoma: an Asian perspective. Dig Dis. 2001;19:263–8.

    Article  CAS  PubMed  Google Scholar 

  3. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–6.

    Article  CAS  PubMed  Google Scholar 

  4. Kloosterman W, Plasterk R. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006;11:441–50.

    Article  CAS  PubMed  Google Scholar 

  5. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.

    Article  CAS  PubMed  Google Scholar 

  6. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.

    Article  CAS  PubMed  Google Scholar 

  8. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299:425–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294:853–8.

    Article  CAS  PubMed  Google Scholar 

  10. Lakshmipathy U, Love B, Adams C, Thyagarajan B, Chesnut JD. Micro RNA profiling: an easy and rapid method to screen and characterize stem cell populations. Methods Mol Biol. 2007;407:97–114.

    Article  CAS  PubMed  Google Scholar 

  11. Michael MZ, O’ Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1:882–91.

    CAS  PubMed  Google Scholar 

  12. Doberstein K, Steinmeyer N, Hartmetz AK, Eberhardt W, Mittelbronn M, Harter PN, et al. MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia. 2013;15:218–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.

    Article  CAS  PubMed  Google Scholar 

  14. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer. 2010;102:883–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Morgan-Fisher M, Wewer UM, Yoneda A. Regulation of ROCK activity in cancer. J Histochem Cytochem. 2013;61:185–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ma W, Wong CC, Tung EK, Wong CM, Ng IO. RhoE is frequently downregulated in HCC and suppresses HCC invasion through antagonizing the Rho/ROCK/MYPT pathway. Hepatology. 2012;57:152–61.

    Article  Google Scholar 

Download references

Acknowledgments

This study was supported by National Natural Science Foundation of China grant (No. 81360274 and No. 31200657).

Author information

Authors and Affiliations

  1. Department of Clinical Laboratory, Kunming General Hospital, Chinese People’s Liberation Army, Daguan Road, Kunming, 650032, Yunnan, China

    Wei Ding, Xuemei Li, Changli Jiang, Yue Zhang & Lan Wang

  2. Department of Orthopedics, Kunming General Hospital of Chinese People’s Liberation Army, Daguan Road, Kunming, 650032, Yunnan, China

    Hongbo Tan

  3. Department of Clinical Hematology, Third Military Medical University, Chongqing, 400038, China

    Chen Zhao

  4. Division of Cellular and Molecular Diagnostics, Center of Laboratory Medicine, Chengdu Military General Hospital, Chengdu, 610083, Sichuan, China

    Zhiqiang Li

Authors
  1. Wei Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hongbo Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chen Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xuemei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhiqiang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Changli Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yue Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wei Ding.

Ethics declarations

Conflicts of interest

None

Informed consents

All specimens were collected in accordance with informed consents of patients, and all procedures complied with the protocol approved by the Ethical Committee of Kunming General Hospital.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ding, W., Tan, H., Zhao, C. et al. MiR-145 suppresses cell proliferation and motility by inhibiting ROCK1 in hepatocellular carcinoma. Tumor Biol. 37, 6255–6260 (2016). https://doi.org/10.1007/s13277-015-4462-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4462-3

Keyword

Search

Navigation